Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
10 pending office actions • 6 art units • 8 examiners • 0 of 10 (0%) have an AI response strategy ready • 21 patents granted in the last 365 days
Florida State University Research Foundation Inc. is currently managing 9 pending office actions within the Chemistry & Materials technology area. These matters are spread across 8 distinct examiners and 7 distinct art units. This distribution shows a diverse prosecution environment where the foundation's applications are being scrutinized by multiple experts across several different specialized departments. The involvement of 7 distinct art units indicates that the foundation's research covers a broad spectrum of chemical and material sciences.
The busiest examiner for this portfolio is HUTTER, GILLIAN A, who is handling 2 pending office actions. While most of the 8 distinct examiners are managing only a single action each, this specific examiner holds a slightly higher share of the workload. With 9 total pending actions, the foundation must coordinate a complex strategy that addresses the unique technical standards and examiner behaviors present across a wide section of the patent office. Practitioners should monitor the 2 pending actions under the busiest examiner for potential synergies in arguments, while remaining mindful of the varied requirements across the other distinct art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (10%) |
| §103 only | 2 (20%) |
| Double-patenting only | 2 (20%) |
| Double-patenting + other | 1 (10%) |
| Multi-statute (no §101) | 4 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUTTER, GILLIAN A | 3 | 54.5% | +46.2% |
| LIN, JASON | 1 | 72.8% | +23.5% |
| HEINCER, LIAM J | 1 | 55.8% | +26.0% |
| KEELING, ALEXANDER W | 1 | 55.9% | +38.1% |
| BAUM, ZACHARY JOHN | 1 | 81.5% | +14.9% |
| EASHOO, MARK | 1 | 37.3% | +35.9% |
| KAPUSHOC, STEPHEN THOMAS | 1 | 46.5% | +53.5% |
| PARISI, JESSICA DANIELLE | 1 | 75.8% | +32.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18930473 | METHOD OF INSTANT STARTUP AND GRID SYNCHRONIZATION OF INVERTER BASED RESOURCES | LIN, JASON | — |
| 18442166 | GLASSY ANTIFOULING COATINGS AND METHODS FOR MAKING AND USING THE SAME | HEINCER, LIAM J | — |
| 18506745 | PULSE SHAPING BURST MODE GAS/LIQUID/PLASMA REACTOR | BAUM, ZACHARY JOHN | — |
| 18356657 | STABILIZED SILOXANE PARTICLES AND METHODS FOR MAKING AND USING THE SAME | EASHOO, MARK | — |
| 18300477 | Molecular Biomarkers for Predicting Patient Response to Steroid Therapy | KAPUSHOC, STEPHEN THOMAS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18065073 | SELECTIVE TREATMENT OF CANCERS HAVING HISTONE H3 MUTATIONS OR ABERRAN TLEVELS OF DNA OR HISTONE METHYLATION, ACETYLATION OR DEFECTS IN HOMOLOGOUS RECOMBINATION | HUTTER, GILLIAN A | 19d |
| 18930473 | METHOD OF INSTANT STARTUP AND GRID SYNCHRONIZATION OF INVERTER BASED RESOURCES | LIN, JASON | — |
| 18901200 | SELECTIVE TREATMENT OF CANCERS HAVING HISTONE H3 MUTATIONS OR ABERRANT LEVELS OF DNA OR HISTONE METHYLATION, ACETYLATION OR DEFECTS IN HOMOLOGOUS RECOMBINATION | HUTTER, GILLIAN A | — |
| 18442166 | GLASSY ANTIFOULING COATINGS AND METHODS FOR MAKING AND USING THE SAME | HEINCER, LIAM J | — |
| 18433570 | BIMETALLIC IRON-COBALT NANOCARBIDE ELECTROCATALYSTS FOR THE OXYGEN EVOLUTION REACTION | KEELING, ALEXANDER W | — |
| 18506745 | PULSE SHAPING BURST MODE GAS/LIQUID/PLASMA REACTOR | BAUM, ZACHARY JOHN | — |
| 18356657 | STABILIZED SILOXANE PARTICLES AND METHODS FOR MAKING AND USING THE SAME | EASHOO, MARK | — |
| 18300477 | Molecular Biomarkers for Predicting Patient Response to Steroid Therapy | KAPUSHOC, STEPHEN THOMAS | — |
| Art Unit | Apps |
|---|---|
| 1625 | 2 |
| 1731 | 1 |
| 1736 | 1 |
| 1767 | 1 |
| 1683 | 1 |
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18930473 | METHOD OF INSTANT STARTUP AND GRID SYNCHRONIZATION OF INVERTER BASED RESOURCES | LIN, JASON | — | §102§103 | Non-Final OA | — | Pending | Oct 29, 2024 |
| 18901200 | SELECTIVE TREATMENT OF CANCERS HAVING HISTONE H3 MUTATIONS OR ABERRANT LEVELS OF DNA OR HISTONE METHYLATION, ACETYLATION OR DEFECTS IN HOMOLOGOUS RECOMBINATION | HUTTER, GILLIAN A | — | DP | Non-Final OA | — | Pending | Sep 30, 2024 |
| 18442166 | GLASSY ANTIFOULING COATINGS AND METHODS FOR MAKING AND USING THE SAME | HEINCER, LIAM J | 1731 | §102§103 | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18433570 | BIMETALLIC IRON-COBALT NANOCARBIDE ELECTROCATALYSTS FOR THE OXYGEN EVOLUTION REACTION | KEELING, ALEXANDER W | — | §103 | Non-Final OA | — | Pending | Feb 06, 2024 |
| 18506745 | PULSE SHAPING BURST MODE GAS/LIQUID/PLASMA REACTOR | BAUM, ZACHARY JOHN | 1736 | §102§103 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18356657 | STABILIZED SILOXANE PARTICLES AND METHODS FOR MAKING AND USING THE SAME | EASHOO, MARK | 1767 | §102§103§112 | Non-Final OA | — | Pending | Jul 21, 2023 |
| 18300477 | Molecular Biomarkers for Predicting Patient Response to Steroid Therapy | KAPUSHOC, STEPHEN THOMAS | 1683 | §101§102§112 | Final Rejection | — | Pending | Apr 14, 2023 |
| 18065073 | SELECTIVE TREATMENT OF CANCERS HAVING HISTONE H3 MUTATIONS OR ABERRAN TLEVELS OF DNA OR HISTONE METHYLATION, ACETYLATION OR DEFECTS IN HOMOLOGOUS RECOMBINATION | HUTTER, GILLIAN A | 1625 | §103DP | Final Rejection | 19d | Pending | Dec 13, 2022 |
| 17303457 | SELECTIVE TREATMENT OF CANCERS HAVING HISTONE H3 MUTATIONS OR ABERRANT LEVELS OF DNA OR HISTONE METHYLATION, ACETYLATION OR DEFECTS IN HOMOLOGOUS RECOMBINATION | HUTTER, GILLIAN A | 1625 | DP | Final Rejection | — | Pending | May 28, 2021 |
| 17090454 | Evaluating Genomic Variation Using Repetitive Nucleic Acid Sequences | PARISI, JESSICA DANIELLE | 1684 | §103 | Non-Final OA | — | Pending | Nov 05, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial